Let's uncover which stocks are experiencing notable gaps during today's session.
Pulmonx Corp LUNG
$1.63
▲ +1.24%
(+$0.02)
Open
$1.60
Prev Close
$1.61
Day Range
$1.51 – $1.85
52W Range
$1.13 – $2.89
Market Cap
$68.85M
Beta
0.27
EPS (TTM)
$-1.29
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-01 |
| Shares Out. | 42,240,000 |
| Website | pulmonx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 296 |
| Revenue | $20.6M |
| Gross Profit | $16.0M |
| Net Income | -$13.7M |
| Free Cash Flow | -$29.4M |
| Total Assets | $120.0M |
| Total Liabilities | $74.2M |
| Equity | $45.8M |
About Pulmonx Corp
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Pulmonx Corp is a publicly traded company under the ticker symbol LUNG on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)